Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Altimmune, Inc. on September 25, 2025. The record date for the meeting was August 12, 2025, with 88,257,253 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 51,688,116 shares were present or represented by proxy, representing 58.6% of issued and outstanding shares, establishing a quorum. The voting outcomes were as follows:
- Proposal 1 (Election of Directors): All 10 director nominees were elected. While all received majority support, significant broker non-votes (29,851,129) were recorded for each nominee. "Withhold" votes ranged from approximately 1.2 million for Jerome Durso to 7.4 million for Catherine Sohn.
- Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young LLP was ratified with 48,959,891 votes "For," 1,355,769 "Against," and 1,372,456 "Abstain."
- Proposal 3 (Say-on-Pay): The advisory vote on executive compensation passed with 14,885,881 votes "For," 6,683,682 "Against," and 267,424 "Abstain." There were 29,851,129 broker non-votes.
- Proposal 4 (Adjournment Authorization): The proposal to authorize adjournment to solicit additional proxies passed with 33,695,815 votes "For," 16,363,206 "Against," and 1,629,095 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the high volume of broker non-votes (29,851,129) on the director election and say-on-pay proposals.
- Confirm the final status of the 10 elected directors and any potential resignations or changes in board composition following the meeting.
- Review the full Proxy Statement for detailed executive compensation data referenced in Proposal 3.
- Check subsequent filings for any operational updates or financial results not included in this governance-focused report.